VDZ方案治疗多发性骨髓瘤疗效观察  

Efficacy of the combined therapy with bortezomib,dexamethasone and zoledronic acid in the treatment of multiple myeloma

作　　者：高珊[1] 付蓉[1] 关晶[1] 王婷[1] 邵宗鸿[1] 

机构地区：[1]天津医科大学总医院血液肿瘤科,天津300052

出　　处：《肿瘤》2009年第6期585-588,共4页Tumor

摘　　要：目的：观察硼替佐米联合地塞米松及唑来磷酸方案（VDZ方案）治疗多发性骨髓瘤（muhiplemyeloma，MM）的疗效和不良反应。方法：10例MM患者接受VDZ方案治疗，28d为1个化疗周期。所有患者均接受1～8个化疗周期的治疗，观察疗效和不良反应。结果：中位随访时间11．6（1～27）个月。治疗总有效率为80％（8／10），其中4例完全缓解，3例为很好的部分缓解，1例为部分缓解；其余1例患者疾病稳定，1例自动出院未予评价。主要不良反应包括周围神经症状、胃肠症状、乏力及不同程度的血小板和白细胞计数下降，经对症治疗后均能缓解。结论：VDZ方案对于初治或复发难治的MM患者疗效确切，尽管可引起一定的不良反应，但经对症治疗后均能改善。Objective：To evaluate the efficacy and safety of bortezomib plus dexamethasone and zoledronic acid （VDZ） in the treatment of multiple myeloma （MM）. Methods：Ten MM patients received VDZ regimen in a 28-day cycle. All the patients received 1 to 8 cycles of chemotherapy. International Uniform Response Criteria for MM was used to evaluate the clinical response of the patients. The adverse events were graded according to the guide of National Cancer Institute Common Terminology Criteria for Adverse E- vents （NCICTCAE, version 3.0）. Results ： The median follow-up duration was 11.6 （ 1 to 27） months. The total response rate was 80% （8/10）. Among them, 4 patients had complete response, 3 patients achieved very good partial response, and 1 patient had partial response. One patient was in stable disease and one patient requested to stop the chemotherapy before evaluation. The main adverse events included peripheral neuropathy, gastrointestinal symptoms, fatigue, and thrombocytopenia and leucopenia at different degrees. All the adverse reactions were ameliorated after treatment. Conclusion ： The VDZ regimen was effective in the treatment of either newlydiagnosed or refractory MM patients. Although VDZ regimen induced some kinds of adverse reactions, the adverse events could be ameliorated after treatment.

关 键 词：多发性骨髓瘤 抗肿瘤联合化疗方案 治疗结果 药物毒性 硼替佐米 唑来磷酸 

分 类 号：R733.3[医药卫生—肿瘤]